Johnson & Johnson Has Dividend Royalty Status. Does That Make It a Buy?
Johnson & Johnson just logged its 64th straight year of dividend growth, but biosimilar threats, a MedTech slowdown, and lingering talc litigation raise a real question about whether that streak justifies buying…